Methods: DNA methylation profiles of peripheral blood leucocytes from 7 patients with early-onset ICAS and 7 perfectly matched controls were interrogated for the first time using the Illumina Infinium Human MethylationEPIC BeadChip. Afterward, functional analysis for differentially methylated genes was conducted. In addition, pyrosequencing verification was performed in an independent cohort comprising 21 patients with earlyonset ICAS and 21 age-and gender-matched controls.
Introduction
Intracranial atherosclerotic stenosis (ICAS) is an important etiology of ischemic stroke and a leading cause of recurrent stroke 1) . Numerous studies have confirmed the racial differences in ICAS, and individuals of Asian, African, and Hispanic ancestry are at higher risk of ICAS 2, 3) . One favored hypothesis is that not only inherited susceptibility but also environmenCopyright©2020 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
pants included in the study.
Study Subjects
The definition of early-onset ICAS is unspecific. In this study, we recruited patients aged younger than 60 years, according to several previously published studies on coronary artery or carotid atherosclerosis 17, 18) . At the stage of chip interrogation, we enrolled 7 patients with ICAS and 7 controls. To eliminate interference from gene methylation induced by other factors as much as possible, we carefully screened and selected a similarly matched control for each patient. The matching factors included age, gender, and history of smoking, drinking, hypertension, diabetes, dyslipidemia, and drug use. In the pyrosequencing verification, a precise pair-match might not be possible, because we had only a limited number of controls for selection. Thus, the matching factors included just age and gender. There were no significant differences between the two groups with regard to demographic and clinical features (Supplementary Table 1 ).
The following inclusion criteria were applied: age ≤ 60 years and intracranial artery atherosclerosis causing ≥ 50% stenosis in one or more major intracranial arteries 19) . In addition, the exclusion criteria were extracranial atherosclerosis with significant stenosis (≥ 50%), hemorrhagic stroke or moyamoya disease (MMD), severe coronary heart disease (CHD) or arrhythmia, hyperthyroidism or hypothyroidism, hematological disease, severe hepatic or renal insufficiency, a history of tumors, chronic inflammation, recent infection, or recent surgery.
Vascular Assessments
Intracranial arteries were assessed by at least one of the following examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA). We assessed the intracranial artery segments, including the intracranial internal carotid artery, anterior cerebral artery, middle cerebral artery, posterior cerebral artery, intracranial vertebral artery, and basilar artery, and if there was a reduction of ≥ 50% in luminal diameter of any of these arterial segments 19) . The exact degree of stenosis was measured by comparing the diameter of the vessel at the site of stenosis (D stenosis) with the normal diameter of the vessel just distal to the stenosis (D distal) using the following formula: % stenosis [1 (D stenosis/D distal)] 100% 19) . Two independent investigators blinded to the clinical information and results of the methylation assay read and verified all images.
cess by which a methyl group is added to a nucleotide, usually cytosine nucleotides, in the presence of cytosine-phosphate-guanine (CpG) 4) . DNA methylation can affect gene expression and chromatin organization 4) , and alterations in DNA methylation patterns might play a role in the progression of certain diseases 4, 5) . Both the global methylation status of the genome and aberrant methylation in certain specific methylated loci have been studied in several atherosclerotic lesions from extracranial carotid, coronary, or ascending aorta arteries [6] [7] [8] . Furthermore, epigenome-wide association studies have linked peripheral blood cell DNA methylation profiles of specific loci to hyperlipidemia, hyperglycemia, and obesity, thus uncovering candidate circulating epigenetic markers of atherosclerosis [9] [10] [11] . The intracranial artery has been reported to have anatomically and physiologically distinct characteristics, such as the structure of the arterial walls and wall shear stress, compared with the extracranial carotid, coronary, or other systemic arteries [12] [13] [14] . Studies on methylation profiling in patients with ICAS are limited. Since it is difficult to obtain intracranial vascular tissue, methylation signatures from the circulation of patients with ICAS hold promise as potential biomarkers that might be useful in clinical practice.
Age-related functional impairments are critical factors contributing to the risk and development of ICAS 1, 15) , and DNA methylation changes may be associated with the aging process 8, 15, 16) . Thus, in order to reduce the influences of age-related dysfunction on both DNA methylation and ICAS, we performed this study focusing only on subjects with early-onset ICAS.
Aim
For the first time, we used a genome-wide DNA methylation analysis (Illumina Infinium Human MethylationEPIC BeadChip, Illumina Inc., San Diego, CA, USA) combined with pyrosequencing approaches to identify novel DNA methylation sites in peripheral blood leucocytes from patients with early-onset ICAS compared with those from controls.
Materials and Methods

Ethics Statement
This study was approved by the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. All procedures were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all partici-
Differential Methylation Analysis
A t-test was used to compare methylation profile differences between the two groups. For quality control, the CpG sites with missing values or the detection of P 0.05 in more than 90% of specimens were eliminated.
Single CpG sites with an absolute value of DiffScore 13 and an absolute ( ) 0.17 were considered differentially methylated loci. The DiffScore is a transformation of the P-value that provides directionality to the P-value based on the difference between the average signals in the patient group vs. the control group. The formula is as follows: DiffScore 10 sgn( ( )) log10(P), ( ) (patients) (controls). For a P-value of 0.05, DiffScore 13.
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analyses
GO and KEGG analyses were applied to determine the roles of the differentially methylated genes.
The pathway data were extracted from two standard public pathway databases: KEGG (http://www. kegg.jp/kegg/pathway.html) and GO (www.geneontology.org). The GO terms and KEGG pathways were considered significantly enriched with unadjusted raw P 0.05 and ranged according to -log10(P) from the lowest to the highest.
Validation by Pyrosequencing
Pyrosequencing assays were performed to validate the results obtained from CpG methylation analysis. Briefly, bisulfite-treated DNA was used for polymerase chain reactions (PCRs) with biotinylated primers using a PyroMark PCR kit (Qiagen). In addition, the biotinylated amplicons were purified to the final PCR product using Streptavidin Sepharose beads. The PCR product was bound to Streptavidin Sepharose HP (Amersham Biosciences, Uppsala, Sweden), and the Sepharose beads containing the immobilized PCR product were purified, washed and denatured using denaturation solution, and rewashed using a Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Qiagen) as recommended by the manufacturer. Pyrosequencing reactions and methylation quantification were carried out on a PSQ96 HS System (Pyrosequencing, Qiagen) using appropriate reagents and protocols. Sequencing controls were included in each run to ensure the fidelity of the measurements. The forward and reverse PCR primers (from 5 to 3 ) used were GTGTTTTAGGTTTGGTTAAGTTTAGTTT and ACCTTCAAAACAAACATACTCTT, and the sequencing primer (from 5 to 3 ) used was AGTTG-TAGGAGTGGG.
Blood and Baseline Data Collection and Definition
Fasting blood samples were collected from the participants in the morning after an overnight fast. Blood specimens were collected in EDTA-treated tubes and then stored at 80 before being assayed. All samples were thawed only once prior to use. Blood biochemistry tests (e.g., fasting blood glucose and blood lipids) were performed at the clinical laboratory in the hospital.
The clinical and demographic characteristics of the enrolled participants, such as gender, age, smoking and drinking status, history of disease, and medication, were recorded. All patients underwent standardized diagnostic tests. Hypertension was defined as a mean systolic blood pressure 140 mmHg and/or a mean diastolic blood pressure 90 mmHg at two measurements, or a medical history of anti-hypertensive drugs. Diabetes mellitus was defined as fasting blood glucose 7.00 mmol/L or a medical history of glucose-lowering drugs. Dyslipidemia was defined as serum triglycerides ≥ 1.69 mmol/L, low-density lipoprotein cholesterol ≥ 3.41 mmol/L, or the use of lipidlowering drugs. Smoking was defined as smoking at the time of stroke or had quit smoking within 1 year, and drinking was defined as 2 standard alcoholic beverages consumed per day.
DNA Extraction and Bisulfite Treatment
Genomic DNA (gDNA) was extracted from leucocytes from venous blood samples using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The purity and concentrations of DNA samples were determined using a NanoDrop 1000 Spectrophotometer and Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). The gDNA samples were bisulfite converted using an EZ DNA Methylation Kit (ZYMO Research, Irvine, CA, USA).
Genome-Wide DNA Methylation Profiling
DNA methylation assessment was performed using the Infinium Human MethylationEPIC BeadChip (Illumina Inc.) to interrogate more than 850,000 CpG positions across the genome. The raw image intensities of the hybridized arrays were scanned using an iScan SQ scanner (Illumina). The obtained raw data were processed and standardized using GenomeStudio software 2011.1 (Illumina), and the background method was chosen as the normalization method. Methylation values were estimated as -values that range between 0 (completely unmethylated) and 1 (completely methylated). The experimental process and technical validation were performed according to the manufacturer's instructions.
Results
Identifying Differential DNA Methylation Sites
We compared genome-wide DNA methylation profiles between the 7 patients with ICAS and the 7 matched controls. The basic characteristics of these subjects are summarized in Table 1 . There were no significant differences in terms of demographic data between the two groups.
A total of 866,091 CpG sites that passed the quality control procedure were analyzed in this study. The scatterplot shows a high correlation of methylation levels between patients and controls (Fig. 1A) . Principal component analysis showed that the majority of patients and controls could be divided into two clusters (Supplementary Fig. 1 ). The Manhattan plot showed the distribution of possible differentially methylated CpG sites on each chromosome (Supplementary Fig. 2) .
Three hundred and eighteen differentially methylated CpG sites, including 183 hypermethylated sites
Statistical Analysis
Data are presented as the mean standard deviation or median (interquartile range) for continuous variables and as count and percentage for categorical variables. The Shapiro-Wilk test was used to test variables for normal distribution. Continuous data were analyzed using a Student's t-test (normal distribution) or the Mann-Whitney U test (non-normal distribution). Categorical data were analyzed using Pearson's 2 test or Fisher's exact test. Receiver operating characteristic (ROC) curve analysis was used to determine diagnostic accuracy, and the cut-off point was calculated by maximizing the sensitivity according to the Youden index. Statistical analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) or MedCalc 12.5 (MedCalc Software, Ostend, Belgium). A P-value 0.05 was considered to indicate statistical significance. . Thus, the genes in which differential methylation sites near the TSS (within 1500 bp) are located were also analyzed.
GO analysis for biological processes revealed that the top 4 terms are associated with inflammationrelated biological processes ( Fig. 2A and Supplementary Table 4 ). Additionally, GO analysis for genes of the different sites near TSSs also supported the enrichment results (Fig. 2B and Supplementary Table 5 ). In particular, the negative regulation of hydrolase activity (GO 0051346) was in the foremost findings in both GO analyses.
KEGG pathway analysis of differentially methylated genes revealed connections between the differentially methylated sites and the enrichment of glycometabolism-related pathways, that is, 3 of the top 5 pathways in the analysis for genes of all differentially methand 135 hypomethylated sites, were identified in patients compared with controls, based on the established standards ( Supplementary Table 2; Fig. 1B) ; of these, 114 sites were located in or around CpG islands (within 4 kilobases of a CpG island). In addition, cluster analysis for different methylation profiles was performed using two-way hierarchical clustering (Fig. 1C) .
Functional Analysis
We then assigned the changed methylation sites to known gene regions. Altogether, we identified 168 differentially methylated genes (Supplementary Table  3 ). To identify common functional characteristics of the differentially methylated genes, GO analysis for biological process terms and KEGG pathway analysis were performed. The differentially enrichment of GO terms and KEGG pathways were identified by unadjusted P. In addition, convincing evidence suggested The X-axis represents the magnitude of the difference in signal intensity between the groups for each probe in the microarray, expressed as ( ) (patients) (controls). The Y-axis represents the absolute DiffScore, and DiffScore 10 sgn( ( )) log10(P). For a P-value of 0.05, DiffScore 13. Significant differences (an absolute DiffScore 13 and an absolute ( ) 0.17) are shown in red. C: Hierarchical cluster analysis of differentially methylated CpG sites identified in this study. The red color in the heat map denotes hypermethylated loci and the blue color denotes hypomethylated loci.
compared with controls [59.56% (49.77%, 88.55%) vs. 44.65% (25.07%, 53.21%); P 0.010; Fig. 4A ], supporting the accuracy of the DNA methylation profile analysis results from the chip interrogation assay. Furthermore, the ROC curve analysis showed that the area under the curve value of cg22443212 that discriminated the presence of ICAS was 0.744 (95% confidence interval, 0.586-0.866; P 0.002; Fig. 4B) , and by the Youden index, the optimal cut-off value for cg22443212 as a diagnostic marker of stroke was 44.65%, which yielded a sensitivity of 95.24% and a specificity of 52.38%.
Discussion
To the best of our knowledge, this is the first study to reveal differential DNA methylation in patients with early-onset ICAS compared with controls. A total of 318 CpG sites were found to be differentially methylated based on the established standards, suggesting an implication of methylation in ylated sites and 4 of the top 5 pathways for genes of the different sites near TSSs (Fig. 3A and Fig. 3B , and Supplementary Table 6 and Table 7 ). In addition, type II diabetes mellitus (KEGG hsa04930) and the insulin signaling pathway (KEGG hsa04910) were in the top findings in both pathway analyses.
Validation by Pyrosequencing
Previous studies have reported that ring finger protein 213 (RNF213) is associated with intracranial vascular lesions 22, 23) , and we identified a methylation site, cg22443212, in the gene body of RNF213 (Rnf213) that showed significant hypermethylation in patients in the chip interrogation assay [ ( ) 0.201 and DiffScore 18.659]. Thus, to verify the differential methylation of cg22443212, pyrosequencing was performed in an independent cohort comprising 21 patients with early-onset ICAS and 21 age-and gender-matched controls (Supplementary Table 1 ). Pyrosequencing analysis showed significant hypermethylation of cg22443212 in patients with ICAS lism, that is, the type II diabetes mellitus and the insulin signaling pathway. It is well known that atherosclerosis is one of the most severe complications associated with type 2 diabetes mellitus. Atherosclerosis occurs earlier and with greater severity in patients with diabetes, suggesting that abnormal glucose metabolism significantly accelerates rates of atherosclerosis. Although information on the methylation regulation of genes involved in the pathophysiology of ICAS is scant, the methylation of glycometabolism-related genes in other atherosclerotic diseases has been reported preliminarily 12, 21, 22) . For instance, GCK, an encoded glucokinase that is a key enzyme of glucose phosphorylation, participates in the aforementioned pathways. A previous study has provided evidence that hypomethylation in the gene body of GCK was significantly associated with the risk of CHD 35) . The authors speculated that the decrease in GCK methylation in CHD cases may influence transcription and gene expression 35) . Additionally, literature has suggested that defects in the insulin signaling pathway result in insulin resistance and contribute to metabolic dysfunction and cardiovascular disease 34) . Recent studies have reported that the mechanism also involves methylation modification: high insulin levels reduce the methylation of leptin and adiponectin and induce the methylation of estrogen receptor , resulting in atherosclerosis 34, 36) . Together, both biological processes and metabolic pathways of the genes of differentially methylated sites in our functional analysis are annotated to numerous atherosclerosis-related processes. Although particular DNA methylation studies of these processes have been limited up to now, methylation modification should represent an attractive molecular mechanism providing new insights into ICAS. Moreover, by comparing our results with other published methylation studies of atherosclerosis 28) , we found that differences exist in both differentially methylated sites and functional analysis. These discrepancies highlight the differences in methylation involved in atherosclerosis between the intracranial artery and other systemic arteries. After all, different anatomical and physiological characteristics are known to exist [12] [13] [14] . Further studies are warranted to unravel the mechanisms involved in methylation regulation.
In this study, pyrosequencing analysis validated the methylation status of cg22443212, a locus in the gene body of Rnf213, showing hypermethylation in patients with ICAS compared with controls, which was consistent with the finding in the methylation BeadChip analysis.
RNF213 is a protein with two consecutive AAA ATPase domains and one ring finger structure 37) . Previous studies have found that RNF213 is linked to a ICAS. Functional analysis annotated differentially methylated sites to atherosclerosis-related processes. In addition, we also identified and validated a significantly hypermethylated site, cg22443212, in the gene Rnf213 for the first time. The methylation level of cg22443212 showed significant diagnostic accuracy in discriminating patients from controls.
Indeed, there is a close connection between atherosclerosis and circulation, and peripheral blood leucocytes are ideal as they play vital roles in atherosclerosis 24, 25) . Accumulating evidence has illustrated the feasibility of DNA methylation profiling using peripheral blood to identify clinical correlations with surrogate markers of atherosclerosis in patients with atherosclerosis-related disease [26] [27] [28] . In addition, studies have reported that the methylation status of some sites in atherosclerotic plaques is similar to blood from patients with extracranial carotid, coronary, or aorta artery atherosclerosis 29, 30) . Moreover, animal studies have demonstrated that changes in the methylation level in peripheral blood and aortas of genetically atherosclerosis-prone mice precede the appearance of any histological sign of atherosclerosis 31) . Thus, we postulate that differential methylation in blood leucocytes may serve as a potential biomarker in clinical practice to monitor the disease and associated comorbidities.
Atherosclerosis is considered a chronic inflammatory condition of the vessel wall. In our GO analysis for biological processes of differentially methylated genes, we further revealed the connections between inflammation-related biological processes and ICAS. For instance, the negative regulation of hydrolase activity was found in the foremost terms. Hydrolases carry out important degradative reactions in the body, cleaving large molecules into fragments that are used as a source of energy or for the excretion of waste materials. Abnormal hydrolase activity is certain to influence metabolic processes. For instance, the gene PRKCZ, encoding protein kinase C (PKC ), is a gene in the pathway of negative regulation of hydrolase activity found in our KEGG analysis. Accumulating studies suggested important roles of PKC in the process of atherosclerosis, such as regulating not only endothelial apoptosis but also tumor necrosis factor--induced endothelial inflammation 32, 33) , promoting monocyte adhesion by increased nuclear factor-B-dependent intercellular adhesion molecule 1 expression 33) , and participating in upregulating the expression of ATP-binding cassette transporter protein family member A1 and promoting cholesterol efflux in THP-1 macrophage-derived foam cells 34) .
In KEGG pathway analysis, we found that the identified differentially methylated sites tended to be located in genes functionally related to glycometabo-pared to DSA 49) . Second, we measured DNA methylation levels in peripheral blood leucocytes rather than in vessels. DNA methylation patterns are largely conserved across tissues and individuals 50) . In addition, considering that harvesting intracranial arteries from a human body is impractical, the research strategy used in this study was ethical and logical. Third, due to the relatively small sample size analyzed in our study, aberrant methylation sites were not analyzed with clinical parameters, and functional analysis were not adjusted using the False discovery rate FDR-controlling procedures or the Bonferroni correction. Besides, differences in DNA collection without adjustments of celltype composition may bring in additional systematic biases 51) . Thus, larger sample sizes are required in future studies. Nevertheless, this study constitutes the first preliminary identification of DNA methylation patterns in patients with ICAS and may help us to understand ICAS-associated genetic-epigenetic interactions.
Conclusion
In conclusion, the present study is a preliminary exploration of DNA methylation in patients with early-onset ICAS and controls. Overall, differentially methylated sites, corresponding genes, and associated biological processes and pathways were identified on the basis of the Infinium Human MethylationEPIC BeadChip interrogation and functional analysis, providing direct evidence that DNA methylation might play an important role in the occurrence and development of ICAS. In addition, we also identified and validated a significantly hypermethylated site in the gene Rnf213 for the first time, supporting the functional relevance of methylation of Rnf213 in ICAS. In the future, studies that further validate the differential methylation of CpG sites are needed.
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The authors declare no conflicts of interest. , although the exact molecular mechanisms by which RNF213 regulates the aforementioned processes remain largely unknown. The relationships of RNF213 with known molecular pathways of the remodeling vasculature, such as noncanonical WNT/Ca 2 /NFAT signaling, have been revealed gradually 38) . In addition, recent reports also showed that RNF213 is associated with immune and inflammatory responses in these processes 39, 40) . Until now, no research on DNA methylation changes in Rnf213 has been reported. Several genetic polymorphisms in this gene have been linked to intracranial vascular lesions, such as MMD 41, 42) , non-MMD ICAS [42] [43] [44] , and cerebral aneurysms 45) . Interestingly, accumulating studies suggested that Rnf213 variants differ between early-and late-onset disorders 41, 46) , which shows that phenotypic heterogeneity in patients cannot be explained solely by gene dosage effects.
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cg22443212 is located upstream of the coding area of AAA ATPases and RING finger domains. RNF213 has two AAA ATPase modules; the first module is essential for assembling RNF213 oligomers, whereas the second module is essential for the disassembly of RNF213 oligomers 37) . Conformational changes in modules are assumed to be related to RNF213 function 37, 47) . In addition, a considerable amount of data supported the idea that the RING finger domain possibly acts as a ubiquitin ligase that covalently modifies substrate proteins with ubiquitin and stimulates intracellular biological processes 37, 48) . Based on previous and present study results, it is reasonable to infer that the hypermethylation of cg22443212 might affect the expression of the downstream genetic information, for example, by blocking the binding of transcription factors or methyl-binding proteins, thus altering the function and/or activity of RNF213. Of course, the precise molecular mechanism by which DNA methylation of Rnf213 causes human ICAS needs further investigation. In all, our findings, together with previously published susceptible mutation sites of Rnf213, suggest that there might be many more genetic or epigenetic abnormalities of Rnf213 in ICAS, and whether these polymorphisms affect gene expression related to DNA methylation needs further studies.
There are several limitations in our study. First, intracranial arteries were assessed by MRA, CTA, or DSA. Different methods may lead to differences in severity assessments. In fact, all the patients received CTA and/or DSA. It has been demonstrated that CTA has high sensitivity and specificity for detecting ≥ 50% stenosis of large intracranial arterial segments com- Fig. 1 . Principal component analysis (PCA) for the DNA methylation levels of the samples PCA was performed using the full microarray data from patients (blue points) and controls (red points) and showed two independent clusters.
Supplementary Fig. 2. Manhattan plots showing distribution of possible differentially methylated CpG sites identified in this study across chromosomes
The black dotted horizontal line indicates the genome-wide significance threshold of an absolute value of DiffScore 13. Continuous variables are expressed as the mean standard deviation or the median (interquartile range). Categorical values are presented as frequencies (percentages). Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein. 
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